Alivus Life Sciences Ltd vs Natco Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1046 as of 13 Apr 15:30 . The P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Natco Pharma Ltd changed from 34.2 on March 2021 to 7.6 on March 2025 . This represents a CAGR of -25.98% over 5 years The Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Natco Pharma Ltd changed from ₹ 15045 crore on March 2021 to ₹ 14287 crore on March 2025 . This represents a CAGR of -1.03% over 5 years The revenue of Alivus Life Sciences Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Natco Pharma Ltd for the Dec '25 is ₹ 705.4 crore as compare to the Sep '25 revenue of ₹ 1463 crore. This represent the decline of -51.78% The ebitda of Alivus Life Sciences Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Natco Pharma Ltd for the Dec '25 is ₹ 216.8 crore as compare to the Sep '25 ebitda of ₹ 679.2 crore. This represent the decline of -68.08% The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Natco Pharma Ltd changed from ₹ 668.5 crore to ₹ 140.4 crore over 7 quarters. This represents a CAGR of -59.01% The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 yearsThe Dividend Payout of Natco Pharma Ltd changed from 30.96 % on March 2021 to 5.8 % on March 2025 . This represents a CAGR of -28.46% over 5 years .

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Natco Pharma Ltd

Natco Pharma Limited was originally incorporated on 19 September 1981 as private limited company as 'Natco Fine Pharmaceuticals Private Limited'.
The name of the company was changed to Natco Pharma Limited and a fresh certificate of incorporation dated 30 December 1994 issued by the RoC, Andhra Pradesh. Natco Pharma is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
The Company's focus is primarily on niche therapeutic areas and complex products.
It sells products in over 40 countries.
FDF products are sold in the United States, India, Europe and the rest of the world (RoW).

FAQs for the comparison of Alivus Life Sciences Ltd and Natco Pharma Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Natco Pharma Ltd?

Market cap of Alivus Life Sciences Ltd is 13,106 Cr while Market cap of Natco Pharma Ltd is 19,945 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Natco Pharma Ltd?

The stock performance of Alivus Life Sciences Ltd and Natco Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Natco Pharma Ltd?

As of May 5, 2026, the Alivus Life Sciences Ltd stock price is INR ₹1067.85. On the other hand, Natco Pharma Ltd stock price is INR ₹1113.6.

How do dividend payouts of Alivus Life Sciences Ltd and Natco Pharma Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Natco Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.